
Hamptons Lowers Outlook on UK Rental Growth as Home Demand Cools
The broker lowered its prediction for 2025 rental growth to 1% from the earlier 4.5%, and trimmed expectations for the following two years. The downgrades have been driven by the transfer of demand from the rental sector to the sales market as mortgage rates have fallen, as well as a weakness in the labor market, Hamptons said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Skift
2 hours ago
- Skift
MakeMyTrip Expands International Listings with Premier Inn's 900+ European Hotels
As direct competition in India is increasing and suppliers are cutting middlemen, MakeMyTrip is moving to international markets to increase supply and distinguish itself. Online travel agency MakeMyTrip has partnered with UK-based hotel chain Premier Inn. Under the partnership, more than 900 Premier Inn properties across the UK, Germany and Ireland have been added to MakeMyTrip's international hotel portfolio. For Premier Inn, the partnership with MakeMyTrip will help increase awareness of the brand in India and neighboring countries. MakeMyTrip's decision was driven by the UK being one of the most preferred destinations for Indian travelers, said Rajesh Magow, co-founder and group CEO of MakeMyTrip. The partnership is a key part of the OTA's strategy to capitalize on India's outbound surge. International Strategy: This is MakeMyTrip's latest effort to expand its international hotel supply. The company has been using a direct contracting strategy to add more hotels to its portfolio, with a focus on high-demand outbound destinations. In a statement, the company said in the past year, it has added more than 2,000 directly contracted hotels across 50 cities in 20 countries. 'These 50 cities collectively account for more than half of India's outbound travel,' MakeMyTrip's statement read. 'Over the past twelve months, we have pursued a focused strategy to deepen our international accommodation offerings across key hubs, particularly in long haul markets such as the UK, Europe, and the U.S.,' said Magow. �


USA Today
10 hours ago
- USA Today
A bill to renew the 'American Dream' of housing just passed a Congressional hurdle
A Senate committee unanimously approved a major housing bill July 29, signaling bipartisan support for an issue that's plaguing constituents in districts around the country. The Renewing Opportunity in the American Dream to Housing Act of 2025 was sponsored by Senator Tim Scott, a Republican from South Carolina, and Senator Elizabeth Warren, a Massachusetts Democrat. The legislation aims to 'increase the supply of affordable housing in America' through a wide range of policies, including increasing construction, making small mortgages more attainable, reforming the appraisal process and supporting manufactured housing, among others. The legislation 'would be the most impactful and comprehensive piece of housing legislation since the Great Recession,' which began in 2007, said analysts at the Bipartisan Policy Center in a summary published after the bill passed through the Senate Banking, Housing, and Urban Affairs Committee. One hint at just how comprehensive the bill is: it incorporates part of at least 27 previously introduced pieces of legislation, the summary explained, of which 23 were introduced with bipartisan sponsors. The national housing crisis has deepened – and it's also becoming more wide-reaching. Both parties' major presidential candidates focused on it on the campaign trail last fall, and legislators around the country remain concerned. Shaun Donovan, CEO and president of Enterprise Community Partners, who served as secretary of the Department of Housing and Urban Development in the Obama administration, told USA TODAY in December, 'There is a political imperative that is much broader than I've ever seen around housing' as nearly every pocket of America, not just pricey coastal cities, becomes unaffordable. Home prices hit a new all-time high in 2024, with the median at $412,500. Using the traditional lender ratio of 31% debt-to-income, a borrower would need an annual income of at least $126,700 to afford a mortgage payment on a home of that price. 'Many people around the country, frustrated with the way we do American politics, wonder, is there any issue that brings this nation together?' said Senator Scott, who chairs the Senate Banking Committee, during the July 29 session. 'I'm here to say hallelujah! We have found one. It is housing.' Read next: The housing crisis threatens the American dream. What's next? Industry groups, including the National Association of Home Builders, the National Association of Realtors, and the Mortgage Bankers Association, released statements in support of the legislation. But even as advocates cheered the committee's step, some cautioned that the bill has a long way to go before it becomes law. The House of Representatives will take it up in the fall, noted the Bipartisan Policy analysts, adding, 'the bill proposes to enhance many existing federal housing programs and create new ones, but does not uniformly propose funding levels for these changes nor propose offsetting budgetary savings or revenue increases.'
Yahoo
12 hours ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio